Sun Xiu, Wolf Marina E
Department of Neuroscience, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.
Eur J Neurosci. 2009 Aug;30(4):539-50. doi: 10.1111/j.1460-9568.2009.06852.x. Epub 2009 Aug 7.
Synaptic scaling has been proposed as a form of plasticity that may contribute to drug addiction but it has not been previously demonstrated in the nucleus accumbens (NAc), a critical region for addiction. Here we demonstrate bidirectional synaptic scaling in postnatal rat NAc neurons that were co-cultured with prefrontal cortical neurons to restore excitatory input. Prolonged activity blockade (1-3 days) with an AMPA receptor antagonist increased cell surface (synaptic and extrasynaptic) glutamate receptor 1 (GluR1) and GluR2 but not GluR3, as well as GluR1/2 co-localization on the cell surface and total GluR1 and GluR2 protein levels. A prolonged increase in activity (bicuculline, 48 h) produced opposite effects. These results suggest that GluR1/2-containing AMPA receptors undergo synaptic scaling in NAc neurons. GluR1 and GluR2 surface expression was also increased by tetrodotoxin alone or in combination with an N-methyl-d-aspartate receptor or AMPA receptor antagonist but not by the l-type Ca(2+) channel antagonist nifedipine. A cobalt-quenching assay confirmed the immunocytochemical results indicating that synaptic scaling after activity blockade did not involve a change in abundance of GluR2-lacking AMPA receptors. Increased AMPA receptor surface expression after activity blockade required protein synthesis and was occluded by inhibition of the ubiquitin-proteasome system. Repeated dopamine (DA) treatment, which leads to upregulation of surface GluR1 and GluR2, occluded activity blockade-induced synaptic scaling. These latter results indicate an interaction between cellular mechanisms involved in synaptic scaling and adaptive mechanisms triggered by repeated DA receptor stimulation, suggesting that synaptic scaling may not function normally after exposure to DA-releasing drugs such as cocaine.
突触缩放被认为是一种可塑性形式,可能与药物成瘾有关,但此前尚未在伏隔核(NAc)中得到证实,而伏隔核是成瘾的关键区域。在这里,我们展示了与前额叶皮质神经元共培养以恢复兴奋性输入的新生大鼠NAc神经元中的双向突触缩放。用AMPA受体拮抗剂进行长时间的活动阻断(1 - 3天)会增加细胞表面(突触和突触外)的谷氨酸受体1(GluR1)和GluR2,但不会增加GluR3,以及细胞表面GluR1/2的共定位和总GluR1和GluR2蛋白水平。活动的长时间增加(荷包牡丹碱,48小时)产生相反的效果。这些结果表明,含有GluR1/2的AMPA受体在NAc神经元中经历突触缩放。单独使用河豚毒素或与N - 甲基 - D - 天冬氨酸受体或AMPA受体拮抗剂联合使用也会增加GluR1和GluR2的表面表达,但L型钙(2+)通道拮抗剂硝苯地平则不会。钴淬灭试验证实了免疫细胞化学结果,表明活动阻断后的突触缩放不涉及缺乏GluR2的AMPA受体丰度的变化。活动阻断后AMPA受体表面表达的增加需要蛋白质合成,并且被泛素 - 蛋白酶体系统的抑制所阻断。重复多巴胺(DA)处理会导致表面GluR1和GluR2上调,从而阻断活动阻断诱导的突触缩放。后一组结果表明参与突触缩放的细胞机制与重复DA受体刺激触发的适应性机制之间存在相互作用,这表明在接触可卡因等释放DA的药物后,突触缩放可能无法正常发挥作用。